Version 1

Iopofosine I 131

Medicine

Extended indication Treatment of patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Iopofosine I 131
Domain Hematology
Reason of inclusion New medicine (specialité)
Main indication CLL
Extended indication Treatment of patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy.
Manufacturer Cellectar
Mechanism of action Unknown
Route of administration Unknown
Therapeutical formulation Unknown
Budgetting framework Intermural (MSZ)
Additional remarks Fabrikant: Cellectar Biosciences

Registration

Registration route Centralised (EMA)
Type of trajectory Unknown
Particularity Unknown
ATMP No
Submission date 2024
Expected Registration 2025
Orphan drug Unknown
Registration phase Clinical trials
Additional remarks NCT02952508

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information